Cost-effectiveness analysis of an antimicrobial stewardship program in Lombardia
Cost-effectiveness Analysis of an Antimicrobial Stewardship Program in Regione Lombardia: "Finalizzata di Rete 2018"
This study is testing whether an Antimicrobial Stewardship program in hospitals can help improve patient outcomes and save money for people with infections caused by tough bacteria.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06388278 on ClinicalTrials.gov |
What this trial studies
This study evaluates the cost-effectiveness of an Antimicrobial Stewardship (AMS) program implemented across 18 hospital facilities in Regione Lombardia. It is a prospective, multicenter, pre-post analysis that aims to assess the efficiency of economic resources allocated to the AMS in patients with infections, particularly those caused by carbapenem-resistant gram-negative bacteria. The study will compare hospital mortality rates before and during the AMS implementation over two six-month phases, providing insights into the program's impact on patient outcomes and resource utilization.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized patients aged 18 years or older who have received antimicrobial therapy.
Not a fit: Patients who do not meet the inclusion criteria, such as those not hospitalized or without relevant ICD-9-CM codes, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved patient outcomes and more efficient use of healthcare resources in managing infections.
How similar studies have performed: Other studies have shown success with similar antimicrobial stewardship approaches, indicating potential for positive outcomes in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All hospitalizations of subjects aged 18 years or older whose Hospital Discharge Form (SDO) contains at least one ICD-9-CM code that belongs to the list of codes that identify hospitalizations that likely included the administration of antimicrobial therapy * Subgroup of the population included for objectives 1 and 3 in which bacteremia due to carbapenem-resistant bacteria has been identified Exclusion Criteria: * patients non included in Inclusion criteria
Where this trial is running
Milan
- IRCCS Fondazione Policlinico of Milan — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Andrea Gori — IRCCS Fondazione Cà Granda Policlinico of Milan
- Study coordinator: Giulia Renisi
- Email: clinicaltrial.malinf@policlinico.mi.it
- Phone: +393887429609
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.